ELEVIDYS for Duchenne Muscular Dystrophy

(ENHANCE Trial)

This trial studies a treatment called ELEVIDYS for individuals with Duchenne Muscular Dystrophy (DMD), a condition that progressively weakens muscles. The main goal is to determine if adding sirolimus, an immunosuppressant drug, can prevent liver issues associated with ELEVIDYS. Participants are divided into two groups: one receives ELEVIDYS with sirolimus, while the other involves a follow-up visit for those who have already received ELEVIDYS. This trial suits males who can walk and have previously used or are eligible to use ELEVIDYS. As a Phase 4 trial, this research highlights that ELEVIDYS is already FDA-approved and effective, aiming to understand its benefits for more patients.

Research has shown that ELEVIDYS, a gene therapy for Duchenne muscular dystrophy, has undergone thorough safety studies. It is approved for children who are at least four years old and can still walk, indicating it has passed strict safety tests for this group.

However, some patients have experienced serious liver problems, including sudden liver failure, particularly in those who cannot walk. Patients with certain genetic changes in the DMD gene should not use ELEVIDYS due to safety concerns.

ELEVIDYS is unique because it aims to treat Duchenne Muscular Dystrophy (DMD) by using gene therapy to introduce a functional version of the dystrophin protein, which is missing or defective in patients with DMD. Most current treatments, like corticosteroids, only manage symptoms and inflammation rather than addressing the root cause. By directly targeting the genetic basis of DMD, ELEVIDYS offers a new approach that could potentially slow disease progression more effectively. Researchers are excited because this method could lead to longer-lasting benefits and improve muscle function in ways current treatments cannot.

Studies have shown that ELEVIDYS, a gene therapy, significantly impacts Duchenne muscular dystrophy (DMD). In one study, patients who received ELEVIDYS improved by 2.88 points on the North Star Ambulatory Assessment (NSAA), a test measuring muscle function, two years after treatment. Research suggests that ELEVIDYS can slow disease progression by about 70-73% for certain physical abilities. Due to these promising results, the FDA has granted ELEVIDYS accelerated approval. While not a cure, ELEVIDYS is expected to increase muscle strength and slow DMD progression in young patients. Participants in this trial will receive ELEVIDYS, with some also receiving sirolimus, glucocorticoids, and antibiotics as part of their treatment regimen.⁶⁷⁸⁹¹⁰